{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:10:28Z","timestamp":1781511028759,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ahj.2014.03.019","type":"journal-article","created":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T14:45:20Z","timestamp":1397313920000},"page":"6-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":225,"title":["A systematic review of statin-induced muscle problems in clinical trials"],"prefix":"10.1016","volume":"168","author":[{"given":"Harsha V.","family":"Ganga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna B.","family":"Slim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ahj.2014.03.019_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an Internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.ahj.2014.03.019_bb0015","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0002-9149(01)01464-3","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin","volume":"87","author":"Downs","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.03.019_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-9-6","article-title":"Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people","volume":"9","author":"Armitage","year":"2009","journal-title":"BMC Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diab Vasc Dis Res"},{"issue":"11","key":"10.1016\/j.ahj.2014.03.019_bb0030","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.1993.00410110029006","article-title":"Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II","volume":"153","year":"1993","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.ahj.2014.03.019_bb0035","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/01.CIR.92.7.1758","article-title":"Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries","volume":"92","author":"Salonen","year":"1995","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2014.03.019_bb0040","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0735-1097(95)00301-0","article-title":"Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation","volume":"26","author":"Pitt","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2014.03.019_bb0045","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","article-title":"Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)","volume":"91","author":"Jukema","year":"1995","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ahj.2014.03.019_bb0050","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2014.03.019_bb0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2014.03.019_bb0060","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9343(96)00333-6","article-title":"Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study","volume":"101","author":"Mercuri","year":"1996","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.ahj.2014.03.019_bb0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1365-2796.1998.00350.x","article-title":"Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease","volume":"244","author":"Bak","year":"1998","journal-title":"J Intern Med"},{"issue":"19","key":"10.1016\/j.ahj.2014.03.019_bb0070","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ahj.2014.03.019_bb0075","first-page":"810","volume":"1","year":"2000","journal-title":"Ital Heart J"},{"issue":"9346","key":"10.1016\/j.ahj.2014.03.019_bb0080","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"9542","key":"10.1016\/j.ahj.2014.03.019_bb0085","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ahj.2014.03.019_bb0090","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0002-9149(93)90858-A","article-title":"Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol\/liter (200 to 300 mg\/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients","volume":"72","year":"1993","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2014.03.019_bb0095","doi-asserted-by":"crossref","first-page":"54C","DOI":"10.1016\/S0002-9149(99)80471-8","article-title":"Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)","volume":"76","author":"Byington","year":"1995","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.ahj.2014.03.019_bb0100","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ahj.2014.03.019_bb0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","article-title":"Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)","volume":"119","author":"Blankenhorn","year":"1993","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.ahj.2014.03.019_bb0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up","volume":"74","author":"Bradford","year":"1994","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2014.03.019_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study","volume":"154","author":"LaRosa","year":"1994","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ahj.2014.03.019_bb0120","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/01.CIR.90.4.1679","article-title":"Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group","volume":"90","author":"Furberg","year":"1994","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0125","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1161\/01.CIR.89.3.959","article-title":"Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial","volume":"89","author":"Waters","year":"1994","journal-title":"Circulation"},{"issue":"9364","key":"10.1016\/j.ahj.2014.03.019_bb0130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.ahj.2014.03.019_bb0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ahj.2014.03.019_bb0145","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2014.03.019_bb0150","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ahj.2014.03.019_bb0155","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2014.03.019_bb0160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.eurheartj.a060485","article-title":"Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study","volume":"15","author":"Keech","year":"1994","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.ahj.2014.03.019_bb0165","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1001\/archinte.1996.00440170097011","article-title":"Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study","volume":"156","author":"Pedersen","year":"1996","journal-title":"Arch Intern Med"},{"issue":"15","key":"10.1016\/j.ahj.2014.03.019_bb0170","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","article-title":"Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin\/Enalapril Coronary Atherosclerosis Trial (SCAT)","volume":"102","author":"Teo","year":"2000","journal-title":"Circulation"},{"issue":"9326","key":"10.1016\/j.ahj.2014.03.019_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"8923","key":"10.1016\/j.ahj.2014.03.019_bb0180","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(94)92082-6","article-title":"Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ahj.2014.03.019_bb0185","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ahj.2014.03.019_bb0190","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"issue":"9645","key":"10.1016\/j.ahj.2014.03.019_bb0195","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ahj.2014.03.019_bb0200","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2014.03.019_bb0205","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0210","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0002-9149(97)00346-9","article-title":"Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])","volume":"80","author":"Herd","year":"1997","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.ahj.2014.03.019_bb0215","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ahj.2014.03.019_bb0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(99)00062-3","article-title":"The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment","volume":"144","author":"Riegger","year":"1999","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ahj.2014.03.019_bb0225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.atherosclerosis.2004.08.033","article-title":"Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives","volume":"178","author":"Anderssen","year":"2005","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ahj.2014.03.019_bb0230","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/euhj.1998.1150","article-title":"A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial","volume":"20","author":"Serruys","year":"1999","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0235","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/01.CIR.0000046488.52939.BF","article-title":"Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function)","volume":"107","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2014.03.019_bb0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2014.03.019_bb0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJM198801073180111","article-title":"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation","volume":"318","author":"East","year":"1988","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2014.03.019_bb0250","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"issue":"23 Suppl. 1","key":"10.1016\/j.ahj.2014.03.019_bb0255","first-page":"III50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2014.03.019_bb0260","first-page":"205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.ahj.2014.03.019_bb0265","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"issue":"9753","key":"10.1016\/j.ahj.2014.03.019_bb0270","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahj.2014.03.019_bb0275","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2013.02.002","article-title":"A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design","volume":"7","author":"Parker","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ahj.2014.03.019_bb0280","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Saf"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:52:27Z","timestamp":1757569947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870314001653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0002870314001653"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.03.019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718463649.793516680","asserted-by":"object"}]},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of statin-induced muscle problems in clinical trials","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}